Advertisements
Feeds:
Posts
Comments

Archive for the ‘Health Care System by Country’ Category


 

Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address

Reporter: Stephen J. Williams, PhD

8:30 AM -9:15

Practical Applications of AI in Cancer

We are far from machine learning dictating clinical decision making, but AI has important niche applications in oncology. Hear from a panel of innovative startups and established life science players about how machine learning and AI can transform different aspects in healthcare, be it in patient recruitment, data analysis, drug discovery or care delivery.

Moderator: Ayan Bhattacharya, Advanced Analytics Specialist Leader, Deloitte Consulting LLP
Speakers:
Wout Brusselaers, CEO and Co-Founder, Deep 6 AI @woutbrusselaers ‏
Tufia Haddad, M.D., Chair of Breast Medical Oncology and Department of Oncology Chair of IT, Mayo Clinic
Carla Leibowitz, Head of Corporate Development, Arterys @carlaleibowitz
John Quackenbush, Ph.D., Professor and Director of the Center for Cancer Computational Biology, Dana-Farber Cancer Institute

Ayan: working at IBM and Thompon Rueters with structured datasets and having gone through his own cancer battle, he is now working in healthcare AI which has an unstructured dataset(s)

Carla: collecting medical images over the world, mainly tumor and calculating tumor volumetrics

Tufia: drug resistant breast cancer clinician but interested in AI and healthcareIT at Mayo

John: taking large scale datasets but a machine learning skeptic

moderator: how has imaging evolved?

Carla: ten times images but not ten times radiologists so stressed field needs help with image analysis; they have seen measuring lung tumor volumetrics as a therapeutic diagnostic has worked

moderator: how has AI affected patient recruitment?

Tufia: majority of patients are receiving great care but AI can offer profiles and determine which patients can benefit from tertiary care;

John: 1980 paper on no free lunch theorem; great enthusiasm about optimization algortihisms fell short in application; can extract great information from e.g. images

moderator: how is AI for healthcare delivery working at mayo?

Tufia: for every hour with patient two hours of data mining. for care delivery hope to use the systems to leverage the cognitive systems to do the data mining

John: problem with irreproducible research which makes a poor dataset:  also these care packages are based on population data not personalized datasets; challenges to AI is moving correlation to causation

Carla: algorithisms from on healthcare network is not good enough, Google tried and it failed

John: curation very important; good annotation is needed; needed to go in and develop, with curators, a systematic way to curate medial records; need standardization and reproducibility; applications in radiometrics can be different based on different data collection machines; developed a machine learning model site where investigators can compare models on a hub; also need to communicate with patients on healthcare information and quality information

Ayan: Australia and Canada has done the most concerning AI and lifescience, healthcare space; AI in most cases is cognitive learning: really two types of companies 1) the Microsofts, Googles, and 2) the startups that may be more pure AI

 

Final Notes: We are at a point where collecting massive amounts of healthcare related data is simple, rapid, and shareable.  However challenges exist in quality of datasets, proper curation and annotation, need for collaboration across all healthcare stakeholders including patients, and dissemination of useful and accurate information

 

9:15 AM–9:45 AM

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

The Promise and Hype of Immunotherapy

Immunotherapy is revolutionizing oncology care across various types of cancers, but it is also necessary to sort the hype from the reality. In his keynote, Dr. Brody will delve into the history of this new therapy mode and how it has transformed the treatment of lymphoma and other diseases. He will address the hype surrounding it, why so many still don’t respond to the treatment regimen and chart the way forward—one that can lead to more elegant immunotherapy combination paths and better outcomes for patients.

Speaker:
Joshua Brody, M.D., Assistant Professor, Mount Sinai School of Medicine @joshuabrodyMD

Director Lymphoma therapy at Mt. Sinai

  • lymphoma a cancer with high PD-L1 expression
  • hodgkin’s lymphoma best responder to PD1 therapy (nivolumab) but hepatic adverse effects
  • CAR-T (chimeric BCR and TCR); a long process which includes apheresis, selection CD3/CD28 cells; viral transfection of the chimeric; purification
  • complete remissions of B cell lymphomas (NCI trial) and long term remissions past 18 months
  • side effects like cytokine release (has been controlled); encephalopathy (he uses a hand writing test to see progression of adverse effect)

Vaccines

  •  teaching the immune cells as PD1 inhibition exhausting T cells so a vaccine boost could be an adjuvant to PD1 or checkpoint therapy
  • using Flt3L primed in-situ vaccine (using a Toll like receptor agonist can recruit the dendritic cells to the tumor and then activation of T cell response);  therefore vaccine does not need to be produced ex vivo; months after the vaccine the tumor still in remission
  • versus rituximab, which can target many healthy B cells this in-situ vaccine strategy is very specific for the tumorigenic B cells
  • HoWEVER they did see resistant tumor cells which did not overexpress PD-L1 but they did discover a novel checkpoint (cannot be disclosed at this point)

 

 

 

 

 

 

 

 

 

Please follow on Twitter using the following #hashtags and @pharma_BI

#MCConverge

#AI

#cancertreatment

#immunotherapy

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

 

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

https://pharmaceuticalintelligence.com/press-coverage/

Advertisements

Read Full Post »


Medcity Converge 2018 Philadelphia: Live Coverage @pharma_BI

Stephen J. Williams: Reporter

MedCity CONVERGE is a two-day executive summit that gathers innovative thought leaders from across all healthcare sectors to provide actionable insight on where oncology innovation is heading.

On July 11-12, 2018 in Philadelphia, MedCity CONVERGE will gather technology disruptors, payers, providers, life science companies, venture capitalists and more to discuss how AI, Big Data and Precision Medicine are changing the game in cancer. See agenda.

The conference highlights innovation and best practices across the continuum—from research to technological innovation to transformations of treatment and care delivery, and most importantly, patient empowerment—from some of the country’s most innovative healthcare organizations managing the disease.

Meaningful networking opportunities abound, with executives driving the innovation from diverse entities: leading hospital systems, medical device firms, biotech, pharma, emerging technology startups and health IT, as well as the investment community.

Day 1: Wednesday, July 11, 2018

7:30 AM

2nd Floor – Paris Foyer

Registration + Breakfast

8:15 AM–8:30 AM

Paris Ballroom

Welcome Remarks: Arundhati Parmar, VP and Editor-in-Chief, MedCity News

8:30 AM–9:15 AM

Paris Ballroom

Practical Applications of AI in Cancer

We are far from machine learning dictating clinical decision making, but AI has important niche applications in oncology. Hear from a panel of innovative startups and established life science players about how machine learning and AI can transform different aspects in healthcare, be it in patient recruitment, data analysis, drug discovery or care delivery.

Moderator: Ayan Bhattacharya, Advanced Analytics Specialist Leader, Deloitte Consulting LLP
Speakers:
Wout Brusselaers, CEO and Co-Founder, Deep 6 AI @woutbrusselaers ‏
Tufia Haddad, M.D., Chair of Breast Medical Oncology and Department of Oncology Chair of IT, Mayo Clinic
Carla Leibowitz, Head of Corporate Development, Arterys @carlaleibowitz
John Quackenbush, Ph.D., Professor and Director of the Center for Cancer Computational Biology, Dana-Farber Cancer Institute

9:15 AM–9:45 AM

Paris Ballroom

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

The Promise and Hype of Immunotherapy

Immunotherapy is revolutionizing oncology care across various types of cancers, but it is also necessary to sort the hype from the reality. In his keynote, Dr. Brody will delve into the history of this new therapy mode and how it has transformed the treatment of lymphoma and other diseases. He will address the hype surrounding it, why so many still don’t respond to the treatment regimen and chart the way forward—one that can lead to more elegant immunotherapy combination paths and better outcomes for patients.

Speaker:
Joshua Brody, M.D., Assistant Professor, Mount Sinai School of Medicine @joshuabrodyMD

9:45 AM–10:00 AM

Paris Foyer

Networking Break + Showcase

10:00 AM–10:45 AM

Paris Ballroom

The Davids vs. the Cancer Goliath Part 1

Startups from diagnostics, biopharma, medtech, digital health and emerging tech will have 8 minutes to articulate their visions on how they aim to tame the beast.

Start Time End Time Company
10:00 10:08 Belong.Life
10:09 10:17 Care+Wear
10:18 10:26 OncoPower
10:27 10:35 PolyAurum LLC
10:36 10:44 Seeker Health

Speakers:
Karthik Koduru, MD, Co-Founder and Chief Oncologist, OncoPower
Eliran Malki, Co-Founder and CEO, Belong.Life
Chaitenya Razdan, Co-founder and CEO, Care+Wear @_crazdan
Debra Shipley Travers, President & CEO, PolyAurum LLC @polyaurum
Sandra Shpilberg, Founder and CEO, Seeker Health @sandrashpilberg

10:45 AM–11:00 AM

Paris Foyer

Networking Break + Showcase

11:00 AM–11:45 AM

Montpellier – 3rd Floor

Breakout: Biopharma Gets Its Feet Wet in Digital Health

In the last few years, biotech and pharma companies have been leveraging digital health tools in everything from oncology trials, medication adherence to patient engagement. What are the lessons learned?

Moderator: Anthony Green, Ph.D., Vice President, Technology Commercialization Group, Ben Franklin Technology Partners
Speakers:
Derek Bowen, VP of Business Development & Strategy, Blackfynn, Inc.
Gyan Kapur, Vice President, Activate Venture Partners
Tom Kottler, Co-Founder & CEO, HealthPrize Technologies @HealthPrize

11:00 AM–11:45 AM

Paris Ballroom

Breakout: How to Scale Precision Medicine

The potential for precision medicine is real, but is limited by access to patient datasets. How are government entities, hospitals and startups bringing the promise of precision medicine to the masses of oncology patients

Moderator: Sandeep Burugupalli, Senior Manager, Real World Data Innovation, Pfizer @sandeepburug
Speakers:
Ingo ​Chakravarty, President and CEO, Navican @IngoChakravarty
Eugean Jiwanmall, Senior Research Analyst for Medical Policy & Technology Evaluation , Independence Blue Cross @IBX
Andrew Norden, M.D., Chief Medical Officer, Cota @ANordenMD
Ankur Parikh M.D, Medical Director of Precision Medicine, Cancer Treatment Centers of America @CancerCenter

11:50 AM–12:30 PM

Paris Ballroom

Fireside Chat with Michael Pellini, M.D.

Building a Precision Medicine Business from the Ground Up: An Operating and Venture Perspective

Dr. Pellini has spent more than 20 years working on the operating side of four companies, each of which has pushed the boundaries of the standard of care. He will describe his most recent experience at Foundation Medicine, at the forefront of precision medicine, and how that experience can be leveraged on the venture side, where he now evaluates new healthcare technologies.

Speaker:
Michael Pellini, M.D., Managing Partner, Section 32 and Chairman, Foundation Medicine @MichaelPellini

12:30 PM–1:30 PM

Chez Colette Restaurant – Lobby

Lunch Reception

1:30 PM–2:15 PM

Paris Ballroom

Clinical Trials 2.0

The randomized, controlled clinical trial is the gold standard, but it may be time for a new model. How can patient networks and new technology be leveraged to boost clinical trial recruitment and manage clinical trials more efficiently?

Moderator: John Reites, Chief Product Officer, Thread @johnreites
Speakers:
Andrew Chapman M.D., Chief of Cancer Services , Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital
Michelle Longmire, M.D., Founder, Medable @LongmireMD
Sameek Roychowdhury MD, PhD, Medical Oncologist and Researcher, Ohio State University Comprehensive Cancer Center @OSUCCC_James

2:20 PM–3:00 PM

Paris Ballroom

CONVERGEnce on Steroids: Why Comcast and Independence Blue Cross?

This year has seen a great deal of convergence in health care.  One of the most innovative collaborations announced was that of Cable and Media giant Comcast Corporation and health plan Independence Blue Cross.  This fireside chat will explore what the joint venture is all about, the backstory of how this unlikely partnership came to be, and what it might mean for our industry.

sponsored by Independence Blue Cross

Moderator: Tom Olenzak, Managing Director Strategic Innovation Portfolio, Independence Blue Cross @IBX
Speakers:
Marc Siry, VP, Strategic Development, Comcast
Michael Vennera, SVP, Chief Information Officer, Independence Blue Cross

3:00 PM–3:15 PM

Paris Foyer

Networking Break + Showcase

3:15 PM–4:00 PM

Montpellier – 3rd Floor

Breakout: Charting the Way Forward in Gene and Cell Therapy

There is a boom underway in cell and gene therapies that are being wielded to tackle cancer and other diseases at the cellular level. FDA has approved a few drugs in the space. These innovations raise important questions about patient access, patient safety, and personalized medicine. Hear from interesting startups and experts about the future of gene therapy.

Moderator: Alaric DeArment, Senior Reporter, MedCity News
Speakers:
Amy DuRoss, CEO, Vineti
Andre Goy, M.D., Chairman and Director of John Theurer Cancer Center , Hackensack University Medical Center

3:15 PM–4:00 PM

Paris Ballroom

Breakout: What’s A Good Model for Value-Based Care in Oncology?

How do you implement a value-based care model in oncology? Medicare has created a bundled payment model in oncology and there are lessons to be learned from that and other programs. Listen to two presentations from experts in the field.

Moderator: Mahek Shah, M.D., Senior Researcher, Harvard Business School @Mahek_MD
Speakers:
Charles Saunders M.D., CEO, Integra Connect
Mari Vandenburgh, Director of Value-Based Reimbursement Operations, Highmark @Highmark

4:00 PM–4:10 PM

Paris Foyer

Networking Break + Showcase

4:10 PM–4:55 PM

Montpellier – 3rd Floor

Breakout: Trends in Oncology Investing

A panel of investors interested in therapeutics, diagnostics, digital health and emerging technology will discuss what is hot in cancer investing.

Moderator: Stephanie Baum, Director of Special Projects, MedCity News @StephLBaum
Speakers:
Karen Griffith Gryga, Chief Investment Officer, Dreamit Ventures @karengg 
Stacey Seltzer, Partner, Aisling Capital
David Shaywitz, M.D., Ph.D., Senior Partner, Takeda Ventures

4:10 PM–4:55 PM

Paris Ballroom

Breakout: What Patients Want and Need On Their Journey

Cancer patients are living with an existential threat every day. A panel of patients and experts in oncology care management will discuss what’s needed to make the journey for oncology patients a bit more bearable.

sponsored by CEO Council for Growth

Moderator: Amanda Woodworth, M.D., Director of Breast Health, Drexel University College of Medicine
Speakers:
Kezia Fitzgerald, Chief Innovation Officer & Co-Founder, CareAline® Products, LLC
Sara Hayes, Senior Director of Community Development, Health Union @SaraHayes_HU
Katrece Nolen, Cancer Survivor and Founder, Find Cancer Help @KatreceNolen
John Simpkins, Administrative DirectorService Line Director of the Cancer Center, Children’s Hospital of Philadelphia

5:00 PM–5:45 PM

Paris Ballroom

Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing

Diagnosing cancer early is often the difference between survival and death. Hear from experts regarding the new and emerging technologies that form the next generation of cancer diagnostics.

Moderator: Heather Rose, Director of Licensing, Thomas Jefferson University
Speakers:
Bonnie Anderson, Chairman and CEO, Veracyte @BonnieAndDx
Kevin Hrusovsky, Founder and Chairman, Powering Precision Health @KevinHrusovsky

5:45 PM–7:00 PM

Paris Foyer

Networking Reception

Day 2: Thursday, July 12, 2018

7:30 AM

Paris Foyer

Breakfast + Registration

8:30 AM–8:40 AM

Paris Ballroom

Opening Remarks: Arundhati Parmar, VP and Editor-in-Chief, MedCity News

8:40 AM–9:25 AM

Paris Ballroom

The Davids vs. the Cancer Goliath Part 2

Startups from diagnostics, biopharma, medtech, digital health and emerging tech will have 8 minutes to articulate their visions on how they aim to tame the beast.

Start Time End Time Company
8:40 8:48 3Derm
8:49 8:57 CNS Pharmaceuticals
8:58 9:06 Cubismi
9:07 9:15 CytoSavvy
9:16 9:24 PotentiaMetrics

Speakers:
Liz Asai, CEO & Co-Founder, 3Derm Systems, Inc. @liz_asai
John M. Climaco, CEO, CNS Pharmaceuticals @cns_pharma 
John Freyhof, CEO, CytoSavvy
Robert Palmer, President & CEO, PotentiaMetrics @robertdpalmer 
Moira Schieke M.D., Founder, Cubismi, Adjunct Assistant Prof UW Madison @cubismi_inc

9:30 AM–10:15 AM

Paris Ballroom

Liquid Biopsy and Gene Testing vs. Reimbursement Hurdles

Genetic testing, whether broad-scale or single gene-testing, is being ordered by an increasing number of oncologists, but in many cases, patients are left to pay for these expensive tests themselves. How can this dynamic be shifted? What can be learned from the success stories?

Moderator: Shoshannah Roth, Assistant Director of Health Technology Assessment and Information Services , ECRI Institute @Ecri_Institute
Speakers:
Rob Dumanois, Manager – reimbursement strategy, Thermo Fisher Scientific
Eugean Jiwanmall, Senior Research Analyst for Medical Policy & Technology Evaluation , Independence Blue Cross @IBX
Michael Nall, President and Chief Executive Officer, Biocept

10:15 AM–10:25 AM

Paris Foyer

Networking Break + Showcase

10:25 AM–11:10 AM

Paris Ballroom

Promising Drugs, Pricing and Access

The drug pricing debate rages on. What are the solutions to continuing to foster research and innovation, while ensuring access and affordability for patients? Can biosimilars and generics be able to expand market access in the U.S.?

Moderator: Bunny Ellerin, Director, Healthcare and Pharmaceutical Management Program, Columbia Business School
Speakers:
Patrick Davish, AVP, Global & US Pricing/Market Access, Merck
Robert Dubois M.D., Chief Science Officer and Executive Vice President, National Pharmaceutical Council
Gary Kurzman, M.D., Senior Vice President and Managing Director, Healthcare, Safeguard Scientifics
Steven Lucio, Associate Vice President, Pharmacy Services, Vizient

11:10 AM–11:20 AM

Networking Break + Showcase

11:20 AM–12:05 PM

Paris Ballroom

Breaking Down Silos in Research

“Silo” is healthcare’s four-letter word. How are researchers, life science companies and others sharing information that can benefit patients more quickly? Hear from experts at institutions that are striving to tear down the walls that prevent data from flowing.

Moderator: Vini Jolly, Executive Director, Woodside Capital Partners
Speakers:
Ardy Arianpour, CEO & Co-Founder, Seqster @seqster
Lauren Becnel, Ph.D., Real World Data Lead for Oncology, Pfizer
Rakesh Mathew, Innovation, Research, & Development Lead, HealthShareExchange
David Nace M.D., Chief Medical Officer, Innovaccer

12:10 PM–12:40 PM

Paris Ballroom

Closing Keynote: Anne Stockwell, Cancer Survivor, Founder, Well Again

Finding Your Well Again
Anne Stockwell discusses her mission to help cancer survivors heal their emotional trauma and regain their balance after treatment. A multi-skilled artist as well as a three-time cancer survivor, Anne learned through experience that the emotional impact of cancer often strikes after treatment, isolating a survivor rather than lighting the way forward. Anne realized that her well-trained imagination as an artist was key to her successful reentry after cancer. Now she helps other survivors develop their own creative tools to help them find their way forward with joy.

Speaker:
Anne Stockwell, Founder and President, Well Again @annewellagain

12:40 PM–12:45 PM

Closing Remarks

 

Please follow on Twitter using the following #hashtags and @pharma_BI

#MCConverge

#cancertreatment

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

 

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

https://pharmaceuticalintelligence.com/press-coverage/

 

 

Read Full Post »


PCI, CABG, CHF, AMI – Two Payment Methods: Bundled payments (hospitalization costs, up to 90 days of post-acute care, nursing home care, complications, and rehospitalizations) vs Diagnosis-related groupings cover only what happens in the hospital.

Reporter: Aviva Lev-Ari, PhD, RN

 

Bundled payments (hospitalization costs, up to 90 days of post-acute care, nursing home care, complications, and rehospitalizations) vs Diagnosis-related groupings cover only what happens in the hospital.

A retrospective, cross-sectional comparison of the BPCI model 2 bundles for percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), congestive heart failure (CHF), and acute myocardial infarction (AMI).

The bundled payments covered hospitalization costs and, in most cases, up to 90 days of post-acute care, including nursing home care, complications, and rehospitalizations. Diagnosis-related groupings cover only what happens in the hospital, while bundled payments cover the entire 90-day episode in most cases.

A Good, Not Simple Idea

Blumenthal and Joynt Maddox agree that the idea of using financial incentives to drive quality improvement is a good one, but one that requires careful consideration and input from clinicians.

“I think policymakers think that it’s easier than it really is and, to be fair, why would a lawyer in DC understand how to make good health policy? I think we really need more clinicians and people with clinical knowledge involved in policymaking,” Joynt Maddox said.

“The idea is to build the bridge between inpatient and outpatient care, by coordinating care better, coordinating transitions better, reducing unnecessary care, and avoiding complications and readmissions,” she added.

An example might be to switch from automatically sending certain patients from the hospital to a nursing home for 30 days. “Maybe they only need 10 days or 1 week, or maybe they can just go home,” she said, but to allow better transitions and lower costs, there needs to be “someone to strategically approach the issue, and a lot of hospitals don’t have that ability.”

“You could argue that all hospitals should have the ability, and I totally agree that we should be doing a better job of organizing across settings, but the problem is that realistically these voluntary programs aren’t going to attract under-resourced hospitals, so this pilot will tell us what is possible in a well-resourced hospital but not much more,” said Joynt Maddox.

To date, the only outcomes reported on the new payment models have been a few evaluations from the federal government. Joynt Maddox recently reported some preliminary outcomes showing a lack of “clinically meaningful changes in access, utilization, or clinical outcomes” with episode-based payment for AMI, CHF, and pneumonia. Her final findings will be published soon.

SOURCE

https://www.medscape.com/viewarticle/899026?nlid=123768_3866&src=WNL_mdplsfeat_180710_mscpedit_card&uac=93761AJ&spon=2&impID=1680511&faf=1#vp_2

Brief Report
June 27, 2018

Factors Associated With Participation in Cardiac Episode Payments Included in Medicare’s Bundled Payments for Care Improvement Initiative

JAMA Cardiol. Published online June 27, 2018. doi:10.1001/jamacardio.2018.1736
Key Points

Question  Are hospitals participating in Medicare’s Bundled Payments for Care Improvement initiative for cardiac bundles different from nonparticipating hospitals in ways that could limit the generalizability of program outcomes to all US acute care hospitals?

Findings  In this cross-sectional study, participation in Bundled Payments for Care Improvement model 2 bundled payments for acute myocardial infarction, congestive heart failure, coronary artery bypass graft surgery, and percutaneous coronary intervention was associated with larger hospital size, non–safety net hospital status, and access to cardiac catheterization laboratories.

Meaning  Outcomes of cardiac bundled payments included in Bundled Payments for Care Improvement may have limited external validity, particularly among small and safety net hospitals with more limited cardiac capabilities.

Abstract

Importance  Medicare’s Bundled Payments for Care Improvement (BPCI) is a voluntary pilot program evaluating bundled payments for several common cardiovascular conditions. Evaluating the external validity of this program is important for understanding the effects of bundled payments on cardiovascular care.

Objective  To determine whether participants in BPCI cardiovascular bundles are representative of US acute care hospitals and identify factors associated with participation.

Design, Setting, and Participants  Retrospective cross-sectional study of hospitals participating in BPCI model 2 bundles for acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery bypass graft, and percutaneous coronary intervention and nonparticipating control hospitals (October 2013 to January 2017). The BPCI participants were identified using data from the Centers for Medicare and Medicaid Services, and controls were identified using the 2013 American Hospital Association’s Survey of US Hospitals. Hospital structural characteristics and clinical performance data were obtained from the American Heart Association survey and Centers for Medicare and Medicaid Services. One hundred fifty-nine hospitals participating in BPCI model 2 cardiac bundles and 1240 nonparticipating control hospitals were compared, and a multivariable logistic regression was estimated to identify predictors of BPCI participation.

Exposures  Bundled payments.

Main Outcomes and Measures  Hospital-level structural characteristics and 30-day risk-adjusted readmission and mortality rates for AMI and CHF.

Results  Compared with nonparticipants, BPCI participants were larger, more likely to be privately owned or teaching hospitals, had lower Medicaid bed day ratios (ratio of Medicaid inpatient days to total inpatient days: 17.0 vs 19.3; P < .001), and were less likely to be safety net hospitals (2.5% vs 12.3%; P < .001). The BPCI participants had higher AMI and CHF discharge volumes, were more likely to have cardiac intensive care units and catheterization laboratories, and had lower risk-standardized 30-day mortality rates for AMI (13.7% vs 16.6%; P = .001) and CHF (11.3 vs 12.4; P = .005). In multivariable analysis, larger hospital size and access to a cardiac catheterization laboratory were positively associated with participation. Being a safety net hospital was negatively associated with participation (odds ratio, 0.3; 95% CI, 0.1-0.7; P = .001).

Conclusions and Relevance  Hospitals participating in BPCI model 2 cardiac bundles differed in significant ways from nonparticipating hospitals. The BPCI outcomes may therefore have limited external validity, particularly among small and safety net hospitals with limited clinical cardiac services.

SOURCE

https://jamanetwork.com/journals/jamacardiology/article-abstract/2686124

Invited Commentary
June 27, 2018

What Can We Learn From Voluntary Bundled Payment Programs?

JAMA Cardiol. Published online June 27, 2018. doi:10.1001/jamacardio.2018.1734

SOURCE

https://jamanetwork.com/journals/jamacardiology/article-abstract/2686128

Read Full Post »


Top 10 Medical Innovations for 2018 by Cleveland Clinic

Reporter: Aviva Lev-Ari, PhD, RN

 

Top 10 for 2018

#1 Hybrid Closed-Loop Insulin Delivery System

#1 Hybrid Closed-Loop Insulin Delivery System

This approach has not just made T1D management easier than ever, it is also getting praise for stabilizing blood glucose at an unprecedented level.


#2 Neuromodulation to Treat Obstructive Sleep Apnea

#2 Neuromodulation to Treat Obstructive Sleep Apnea

While C.P.A.P. is the gold standard treatment for OSA, the risk of misuse or discontinued use has created an opportunity for innovators to search for a less intrusive way to treat it. The result is ne


#3 Gene Therapy for Inherited Retinal Diseases

#3 Gene Therapy for Inherited Retinal Diseases

In 2018 gene therapy is expected to make its comeback with expected FDA approvals for a variety of inherited retinal diseases (“IRDs”).


#4 The Unprecedented Reduction of LDL Cholesterol

#4 The Unprecedented Reduction of LDL Cholesterol

These new drugs are taking cholesterol to low levels never seen before.


#5 The Emergence of Distance Health

#5 The Emergence of Distance Health

In 2018, the prevalence of connectivity enables distance health.


#6 Next Generation Vaccine Platforms

#6 Next Generation Vaccine Platforms

In 2018, innovators will be upgrading the entire vaccine infrastructure to support the rapid development of new vaccines (a concept that was #1 on the Top 10 Medical Innovations for 2015).


#7 Arsenal of Targeted Breast Cancer Therapies

#7 Arsenal of Targeted Breast Cancer Therapies

For breast cancer patients that are BRCA1 or BRCA2 positive, there is new hope for a targeted therapy that is already seeing success in the ovarian cancer market.


#8 Enhanced Recovery After Surgery

#8 Enhanced Recovery After Surgery

After seeing substantial growth in hospital readmissions and an opioid epidemic spiraling out of control, it is clear that physicians need to overhaul the post-surgery strategies currently in use.


#9 Centralized Monitoring of Hospital Patients

#9 Centralized Monitoring of Hospital Patients

Centralized monitoring has emerged as the answer, as part of a “mission control” operation in which off-site personnel use advanced equipment monitor patients.


#10 Scalp Cooling for Reducing Chemotherapy Induced Hair Loss

#10 Scalp Cooling for Reducing Chemotherapy Induced Hair Loss

The practice of “Scalp Cooling” has been shown to be highly effective for preserving hair in women receiving neoadjuvant or adjuvant chemotherapy for early-stage breast cancer.

SOURCE

Read Full Post »


This Is America’s Richest Zip Code

Read Full Post »


Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Hepatitis B virus can cause serious, long-term health problems, such as liver disease and cancer, and can spread from mother-to-child during delivery. According to the latest estimates from the World Health Organization (WHO), approximately 257 million people in 2015 were living with the virus. Countries in Asia have a high burden of hepatitis B. There is no cure, and antiviral drugs used to treat the infection usually need to be taken for life.

 

To prevent infection, WHO recommends that all newborns receive their first dose of hepatitis B vaccine within 24 hours of delivery. Infants born to hepatitis B-infected mothers are also given protective antibodies called hepatitis B immune globulin (HBIG). However, mother-to-child transmission can still occur in women with high levels of virus in their blood, as well as those with mutated versions of the virus.

 

Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen — administration of hepatitis B vaccine and protective antibodies at birth — to explore the drug’s potential effects on mother-to-child transmission rates. The results appear in the New England Journal of Medicine.

 

The present study was conducted at 17 hospitals of the Ministry of Public Health in Thailand. It screened more than 2,500 women for eligibility and enrolled 331 pregnant women with hepatitis B. The women received placebo (163) or TDF (168) at intervals from 28 weeks of pregnancy to two months after delivery. All infants received standard hepatitis B preventatives given in Thailand, which include HBIG at birth and five doses of the hepatitis B vaccine by age 6 months (which differs from the three doses given in the United States). A total of 294 infants (147 in each group) were followed through age 6 months.

 

Three infants in the placebo group had hepatitis B infection at age 6 months, compared to zero infants in the TDF treatment group. Given the unexpectedly low transmission rate in the placebo group, the researchers concluded that the addition of TDF to current recommendations did not significantly reduce mother-to-child transmission of the virus.

 

According to the study, the clinical trial had enough participants to detect statistical differences if the transmission rate in the placebo group reached at least 12 percent, a rate observed in previous studies. Though the reasons are unknown, the researchers speculate that the lower transmission rate seen in the study may relate to the number of doses of hepatitis B vaccine given to infants in Thailand, lower rates of amniocentesis and Cesarean section deliveries in this study, or the lower prevalence of mutated viruses that result in higher vaccine efficacy in Thailand compared to other countries.

 

References:

 

https://www.nih.gov/news-events/news-releases/antiviral-drug-not-beneficial-reducing-mother-child-transmission-hepatitis-b-when-added-existing-preventatives

 

https://www.ncbi.nlm.nih.gov/pubmed/29514030

 

https://www.ncbi.nlm.nih.gov/pubmed/29514035

 

https://www.ncbi.nlm.nih.gov/pubmed/25240752

 

https://www.ncbi.nlm.nih.gov/pubmed/28188612

 

Read Full Post »


2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts  | Westin Copley Place

https://worldmedicalinnovation.org/

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

Announcement

Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

On 5/2015

4/2018

All TWEETS from LPBI’s Twitter.com handles at

#WMIF18

@pharma_BI

@AVIVA1950

Monday, April 23, 2018

 

7:00 am – 8:00 am
GE Foyer
7:00 am – 8:00 am
Nuance Foyer
8:00 am – 11:30 am
NVIDIA Ballroom
First Look: The Next Wave of AI Breakthroughs in Health Care

Early career Harvard Medical School investigators kick-off the 2018 World Medical Innovation Forum with rapid fire presentations of their high potential new technologies. Nineteen rising stars from Brigham Health and Massachusetts General Hospital will give ten-minute presentations highlighting their discoveries and insights that will disrupt the field of artificial intelligence. This session is designed for investors, leaders, donors, entrepreneurs and investigators and others who share a passion for identifying emerging high-impact technologies. To view speakers and topics, click here.

Moderator: Trung Do
  • VP, Business Development, Innovation, PHS
Moderator: Clare Tempany, MD
  • Vice Chair of Research at the Department of Radiology, BWH; Ferenc Jolesz MD Professor of Radiology, HMS
11:45 am – 1:00 pm
3rd Floor and 7th Floor
Discovery Café Workshops

Lunch with Top Leadership from across Partners HealthCare and Industry.

Seven intensive workshops addressing cutting-edge artificial intelligence topics. To view topics and speakers, click here

1:00 pm – 1:20 pm
1:20 pm – 1:45 pm
NVIDIA Ballroom
Opening Remarks
  • Governor of the Commonwealth of Massachusetts
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
  • CEO, PHS
1:45 pm – 2:25 pm
NVIDIA Ballroom
Reflecting on the Impact of AI at the Bed and the Bench: Chairs Roundtable

Senior clinical leaders, current and past Forum Chairs, will share perspectives on the range of impact of AI on clinical practice. Discussion will highlight the rapid evolution of AI as a practical clinical tool and short and mid-term prospects for adoption in cancer, cardiovascular and neurological care.

Moderator: Sue Siegel
  • CIO and CEO, Business Innovations, GE
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
  • Vice Chair for Scientific Innovation, Department of Medicine, BWH; Chief Executive, One Brave Idea, BWH; Associate Professor of Medicine, HMS; 2017 Forum Co-Chair
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair
  • Chief, Cardiology Division, MGH; Professor of Medicine, HMS; 2017 Forum Co-Chair
2:25 pm – 3:15 pm
NVIDIA Ballroom
Can AI Based Drug Development Feed A Hungry Pipeline?

Given the scarcity of late-stage assets, prolonged timelines and enormous costs of bringing drugs to market, AI-based approaches to target discovery, drug design and drug repurposing hold significant promise to positively disrupt the existing R&D paradigm.

  • Chief Data Officer, Broad Institute; Cardiologist, BWH; Venture Partner, Google Ventures
  • CEO, Exscientia
  • Director, Center for Genomic Medicine, MGH; Ofer and Shelly Nemirovsky MGH Research Scholar; Associate Professor of Medicine, HMS
  • EVP and CSO, R&D, Bristol-Myers Squibb
  • CEO, BERG
  • SVP, Strategy, Commercialization & Innovation, Amgen
3:15 pm – 4:05 pm
NVIDIA Ballroom
Smart EHRs: AI for All

The first wave of EHR adoption has focused primarily on digitizing the patient record – with a more recent focus on building interactive clinical decision support capabilities. Development and implementation of CDS applications currently  requires  clinical staff to observe trends in data, develop protocols to act on these trends and work with technical staff to codify the logic into executable form. As NLP and computer vision capabilities become more advanced, algorithms will identify and propose actions reflecting patterns in the data. The panel will discuss existing challenges and whether AI technology will ultimately support an unsupervised learning approach in the EHR to identify trends and possible responses at both the patient and population level?

  • SVP and CMO, MGH
  • CEO, Health Catalyst
  • Director, Analytics & Machine Learning, Epic
  • President, Digital, Persistent Systems
  • CEO, Picnic Health
  • CEO, Wolters Kluwer Health
4:05 pm – 4:55 pm
NVIDIA Ballroom
AI and the Cost of Trials: The Impact of Real World and Real Time Evidence

AI based approaches to conduct faster and more efficient clinical trials are beginning to emerge. Current approaches include applying predictive tools to perform more targeted patient recruitment and more accurate eligibility assessment. Panelists will discuss timelines for AI technology to have a measurable effect on trial cost and time to conduct the trial. Bottlenecks to applying this technology at scale and whether there will be a measurable effect on the cost of bringing drugs to market over the next decade will also be examined.

  • Partner, Google Ventures; Instructor in Medicine, BWH
  • CMO, CSO & SVP Oncology, Flatiron Health
  • VP, Research IT, Eli Lilly and Company
  • CEO, GNS Healthcare
  • CEO, BenevolentAI
  • Senior Advisor, R&D, Bayer
  • Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS
5:00 pm – 6:00 pm
Nuance Foyer

Tuesday, April 24, 2018

 

7:15 am – 7:50 am
Nuance Foyer
7:50 am – 8:00 am
NVIDIA Ballroom
Opening Remarks
  • Chief Innovation Officer, PHS; President, Partners HealthCare International, PHS
8:00 am – 8:50 am
NVIDIA Ballroom
Will AI Bend the Cost and Access Curve

Historical barriers have driven increased medical costs and decreasing access since the 1960s. The “Iron Triangle of Healthcare” continues to represent a tenuous balance of quality, cost and accessibility – economists have lamented attempts to optimize one characteristic at the expense of the others. The accumulation of innovations in care delivery (e.g. shift to lower cost providers and settings), population management, value based reimbursement and hospital administration are having a measurable effect. Can AI based technologies accelerate the pace of innovation and finally bend the cost and access curves in the US?

Moderator: Timothy Ferris, MD
  • CEO, MGPO
  • SVP and CMO, Humana
  • CEO, Cyft, Inc.
  • Vice Chairman, Investment Banking and Managing Director, Lazard Freres
8:50 am – 9:40 am
NVIDIA Ballroom
Drug Therapy Redefined Through Machine Learning

The drug development process is highly complex and has many drivers. The panel will discuss the strategic impact of AI on the entire process and the implications for healthcare overall. How will the combination of factors – research strategy, drug development, regulatory approvals, reimbursement and clinical effectiveness – be influenced by the implementation of AI. Panelists will discuss short and mid-term prospects and whether AI will ultimately lead to a restructuring of the pharma model to develop new therapies.

  • Partner, Atlas Venture
  • President, Novartis Institutes for Biomedical Research
  • CSO, Relay Therapeutics
  • SVP, Global Head of Data Sciences, Johnson & Johnson
  • CSO, Datavant
  • Global Head of Digital and Personalized Health Care Partnering, Roche
9:40 am – 10:10 am
NVIDIA Ballroom
1:1 Fireside Chat: Atul Gawande, MD
Introduction by: John Fish
  • CEO, Suffolk; Chairman of Board Trustees, Brigham Health
  • President, Brigham Health; Professor of Medicine, HMS
  • Executive Director, Ariadne Labs; Samuel O. Thier Professor of Surgery, HMS; Surgeon, BWH
10:10 am – 10:25 am
Nuance Foyer
10:25 am – 11:15 am
NVIDIA Ballroom
Data Engineering in Healthcare: Liberating Value

The promise of machine learning and big data in in healthcare seems boundless – but healthcare data is massive and complex, and organizing and managing this data is the first step to an AI-empowered healthcare system.  Technology giants are investing in solutions to overcome these data engineering challenges, but with many visions of the future of healthcare data jockeying for dominance, what will the future of healthcare data really look like?  Can we finally liberate the value of data for patient care? And how will it happen?

Moderator: Mark Michalski, MD
  • Executive Director, MGH & BWH CCDS
  • ‎Director of Healthcare Research, Microsoft Research
  • VP and Global CTO, Sales, Dell EMC
  • SVP and CMO, Qualcomm Life
  • VP, Healthcare, Google Cloud
  • Chief Research Information Officer, PHS; Associate Professor of Neurology, HMS
  • CTO, Cognitive Collaboration Group, Cisco
11:15 am – 11:45 am
NVIDIA Ballroom
1:1 Fireside Chat: Jensen Huang, CEO, NVIDIA
Introduction by: Scott Sperling
  • Co-President, Thomas H Lee Partners; Chairman of the Board of Directors, PHS
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • CEO, NVIDIA
12:00 pm – 1:00 pm
GE Ballroom
12:30 pm – 1:00 pm
GE Ballroom
1:1 Fireside Chat: Paul Ricci, Former Chairman and CEO of Nuance Communications
Introduction by: Cathy Minehan
  • Managing Director, Arlington Advisory Partners; Chairman, Board of Trustees, MGH
Moderator: James Brink, MD
  • Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS
  • Former Chairman and CEO, Nuance Communications
1:00 pm – 1:10 pm
1:10 pm – 2:00 pm
NVIDIA Ballroom
AI and Gene Sequencing

Gene sequencing technology has evolved considerably over the last 10 years, dramatically decreasing the cost to sequence a human genome. As the costs associated with the technical assay continue to decrease, data interpretation and reporting has become the new bottleneck. Can AI and ML based approaches be applied to better understand how genetic mutations play a role in diseases like cancer – where the high rate of mutation makes treatment challenging? And will continued democratization of genetic information help to accelerate the pace of innovation in the field?

Moderator: Heidi Rehm, PhD
  • Chief Laboratory Director, Laboratory for Molecular Medicine, PHS Personalized Medicine; Associate Professor of Pathology, BWH and HMS
  • Executive Director, Worldwide R&D, Pfizer
  • Director, Bioinformatics Program, Cancer Center and Department of Pathology, MGH; Director, Institute Member, Broad Institute; Associate Professor of Pathology, HMS
  • Director, Computational Pathology and Director, Technology Development, Center for Integrated Diagnostics, MGH; Assistant Professor, Pathology, HMS
  • CEO, Freenome
  • SVP, Product Development, Illumina, Inc.
2:00 pm – 2:50 pm
NVIDIA Ballroom
Tangible Returns on the AI Value Proposition

Fueled by billions in venture investments, hundreds of new companies have emerged worldwide to develop and apply AI in health care. Beyond the US, China’s high AI priority has resulted in a vast array of technology driven start-ups. Global investors will discuss which area of machine learning will have the earliest meaningful impact? How do investors critically assess differentiation in such a crowded field? How are investment priorities set among the many divergent categories where AI will take hold?

Moderator: Meg Tirrell
  • Reporter, CNBC
  • Managing Director, Santé Ventures
  • VP, Venture, Innovation, PHS
  • Partner, Polaris Partners
  • Partner, Andreessen Horowitz
  • Managing Director, Northern Light Venture Capital
2:50 pm – 3:40 pm
NVIDIA Ballroom
CEO Roundtable: The AI Opportunity as Foundational Change

Chief executives share perspectives on the impact of AI on their respective companies and industry segments. How prominently does AI figure into current investment strategies? And how are they measuring return on existing investments in AI? Panelist will be asked to take a position on whether AI is a truly transformational technology.

Moderator: Peter Slavin, MD
  • President, MGH
  • Chief Innovation Officer, GE Healthcare
  • CEO, Philips
  • CEO, Vertex
  • CEO, Siemens Healthineers
3:40 pm – 3:50 pm
NVIDIA Ballroom
Announcement of IDG Awardees
  • Chair, Department of Radiology, BWH; Philip H. Cook Professor of Radiology, HMS
  • Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS
3:50 pm – 4:40 pm
NVIDIA Ballroom
Regulating AI in Healthcare, Requirements and Challenges

The increasing application of AI in health products puts pressure on the historical model of regulation – among them the agile development cycles and continuous learning environment that support AI / machine learning based algorithms. Panelists will discuss the regulatory approaches including the FDA’s recently announced Software Precertification pilot program.

Moderator: Michael Jaff, DO
  • President, NWH, PHS, Professor of Medicine, HMS
  • CEO, Arterys
  • Chief Regulatory Officer, Sanofi
  • VP and GM, Healthcare Digital Solutions, GE Healthcare
  • Associate Director for Digital Health, FDA
4:40 pm – 5:30 pm
NVIDIA Ballroom
AI in Hospital Environments: The Learning Provider

Health systems are actively evaluating strategies to drive efficiency throughout hospital operations. The deployment of AI based technologies to automate organizational tasks (e.g. medical coding / billing, prior authorizations) and optimize resource utilization (e.g. smart scheduling, no-show prediction) promises to help hospital systems adapt to changing macro-economic factors. This panel will discuss the role of AI in hospital operations and assess various approaches to reduce healthcare administration costs and increase efficiency.

Moderator: Adam Landman, MD
  • VP and CIO, Brigham Health
  • Executive Director, IT, Personalized Medicine, PHS
  • Partner, Optum Ventures
  • CEO, Change Healthcare
  • CEO, Qventus
  • Co-Founder, Director, PokitDok
5:30 pm – 6:30 pm
GE Foyer

Wednesday, April 25, 2018

 

7:00 am – 7:30 am
Nuance Foyer
7:30 am – 8:20 am
NVIDIA Ballroom
Reconceiving Medical Devices in an AI Dominated Environment

Medical device companies are focused on developing smaller, faster and smarter devices. New technologies will enhance the function of medical devices throughout patient care. Leveraging AI technology to more effectively interact with patients and inform / facilitate outcomes enables smart devices that can learn and improve performance over time. The nature of AI panel based devices, the challenges inherent in developing them and how such devices can evolve over the next 5 years and beyond will be examined.

Moderator: Pat Fortune, PhD
  • VP, Market Sectors, Innovation, PHS
  • CEO, Bay Labs
  • SVP, Chief Medical and Scientific Officer, Medtronic
  • Founder and CEO, Butterfly Network
  • Associate Chief, Cardiology Division, MGH; Professor of Medicine, HMS
8:20 am – 8:50 am
NVIDIA Ballroom
Fireside Chat: Seema Verma, Administrator, Centers for Medicare and Medicaid Services
Moderator: Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair
  • Administrator, Centers for Medicare and Medicaid Services
8:50 am – 9:20 am
NVIDIA Ballroom
Fireside Chat: Paying for AI: Thinking Strategically About Reimbursements and Acceptance

Understanding how AI will be absorbed into a highly defined payment system is crucial to determining the rate and breadth that the technology will play in health care in the next decade. Two senior leaders will share their perspectives on how the technology will be paid for and what mechanisms will be used to arbitrate the scope and timing of those payments.

Moderator: Peter Markell
  • EVP Administration and Finance, CFO and Treasurer, PHS
  • CEO, BCBS of North Carolina
  • CEO, OptumInsight & Enterprise Growth Officer, Optum
9:20 am – 9:50 am
NVIDIA Ballroom
1:1 Fireside Chat: Vasant Narasimhan, MD, CEO, Novartis
Moderator: Gregg Meyer, MD
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair
  • CEO, Novartis
9:50 am – 10:40 am
NVIDIA Ballroom
Machine Learning in Image Analysis: A Diagnostician’s Best Friend…or Replacement?

Diagnostic imaging is among the clinical fields receiving the greatest attention in the early stages of AI in healthcare. Even in this initial phase it appears that the technology may have profound effects on one of the most resource intensive fields in medicine. Panelists will consider the broad implications as well as topics such as how will role of radiologists evolve? Will AI tools ever become advanced enough to make decisions autonomously within the clinical workflow?

Moderator: Giles Boland, MD
  • Chair, Department of Radiology, BWH; Philip H. Cook Professor of Radiology, HMS
  • CEO, PathAI
  • VP, Medical Imaging Technology, Siemens Healthineers
  • Co-Founder and Chairman, Zebra Medical Vision
  • CEO, GE Healthcare Imaging
  • Chief, Breast Imaging Division, MGH; Professor of Radiology, HMS
10:40 am – 10:50 am
Nuance Foyer
10:50 am – 11:20 am
NVIDIA Ballroom
1:1 Fireside Chat: John Kelly, PhD, SVP, Cognitive Solutions and Research, IBM
Moderator: James Noga
  • VP and CIO, PHS
  • SVP, Cognitive Solutions and Research, IBM
11:20 am – 12:10 pm
NVIDIA Ballroom
Illuminating the Path to Clinician Empowerment

The sacred exchange between patient and clinician at the heart of medicine is increasingly under duress driven by a range of factors. Increasing clinician burnout is recognized as among the many negative consequences of this trend. Panelists will discuss how AI may improve the quality of the patient encounter, clinician workflow and ultimately clinician quality of life. Panelist will discuss how the new technology can meet these objectives when earlier information based technologies may have exacerbated the challenge.

Moderator: Sree Chaguturu, MD
  • VP, Population Health Management, PHS
  • SVP, New Business Development, Healthcare Division, Nuance
  • Chief Health Strategy Officer, US Health & Life Sciences, Microsoft
  • CEO, Robin AI
  • Chief Medical Information Officer, MGPO
12:10 pm – 1:10 pm
NVIDIA Ballroom
Disruptive Dozen: 12 AI Technologies That Will Reinvent Care

The culture of innovation throughout Partners HealthCare naturally fosters robust discussions about new “disruptive” technologies and which ones will have the biggest impact on health care. The Disruptive Dozen was created to identify and rank the technologies that Partners faculty feel will break through over the next decade to significantly improve health care. This year, the Disruptive Dozen focuses on relevant advances and opportunities in artificial intelligence (AI).

  • Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
1:10 pm – 1:15 pm
NVIDIA Ballroom
Last Look
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2018 Forum Co-Chair
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2018 Forum Co-Chair

*Panels and speakers are subject to change.

Highlighted Presenters

Jensen Huang

CEO, NVIDIA

Vasant Narasimhan MD

CEO, Novartis

Paul Ricci

Former Chairman and CEO, Nuance Communications

Atul Gawande MD

Executive Director, Ariadne Labs; Samuel O. Thier Professor of Surgery, HMS; Surgeon, BWH

Seema Verma

Administrator, Centers for Medicare and Medicaid Services

Sue Siegel

CIO and CEO, Business Innovations, GE

Frans van Houten

CEO, Philips

Bernd Montag PhD

CEO, Siemens Healthineers

Terri Bresenham

Chief Innovation Officer, GE Healthcare

John Kelly PhD

SVP, Cognitive Solutions and Research, IBM

Karim Karti

CEO, GE Healthcare Imaging

Jonathan Rothberg PhD

Founder and CEO, Butterfly Network

Jay Bradner MD

President, Novartis Institutes for Biomedical Research

Colin Hill

CEO, GNS Healthcare

Amy Abernethy MD, PhD

CMO, CSO & SVP Oncology, Flatiron Health

Thomas Lynch MD

EVP and CSO, R&D, Bristol-Myers Squibb

Diana Nole

CEO, Wolters Kluwer Health

Roy Beveridge MD

SVP and CMO, Humana

Fabien Beckers PhD

CEO, Arterys

Peter Orszag PhD

Vice Chairman, Investment Banking and Managing Director, Lazard Freres

Georgia Papathomas PhD

SVP, Global Head of Data Sciences, Johnson & Johnson

Punit Soni

CEO, Robin AI

Dan Burton

CEO, Health Catalyst

Jean-François Formela MD

Partner, Atlas Venture

Patrick Conway MD

CEO, BCBS of North Carolina

Jackie Hunter PhD

CEO, BenevolentAI

Greg Moore MD, PhD

VP, Healthcare, Google Cloud

Noga Leviner

CEO, Picnic Health

Leonard D’Avolio PhD

CEO, Cyft, Inc.

Vijay Pande PhD

Partner, Andreessen Horowitz

Iain Buchan MD

‎Director of Healthcare Research, Microsoft Research

Mark Murcko PhD

CSO, Relay Therapeutics

Andrew Hopkins

CEO, Exscientia

Gabriel Otte

CEO, Freenome

Joseph Scheeren PharmD

Senior Advisor, R&D, Bayer

Susan Tousi

SVP, Product Development, Illumina, Inc.

Lisa Maki

Co-Founder, Director, PokitDok

Timothy Tuttle PhD

CTO, Cognitive Collaboration Group, Cisco

Seth Hain

Director, Analytics & Machine Learning, Epic

Featured Speakers

Note: speakers are subject to change.

Read Full Post »

Older Posts »